NCT00133315

TNFalfa Blocking Treatment of Spondylarthropathies

TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (planned)
• Sponsor: Hvidovre University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to establish a Danish cohort of spondylarthropathy (SpA) patients who are being treated with TNFalfa blockers. By following the TNFalfa blocking treated patients the researchers want to identify better biomarkers for disease activity and disease progression. In addition, the researchers want to identify predictors for disease progression.

Conditions

• Spondylarthropathies
• Ankylosing Spondylitis
• Psoriatic Arthritis

Interventions

Type	Name	Description
DRUG	Infliximab
DRUG	Etanercept
DRUG	Adalimumab

Timeline

• Start date: 2004-09-01
• Completion: 2007-04-01
• First posted: 2005-08-23
• Last updated: 2007-04-10

Locations

9 sites across 1 country: Denmark